1 day+0.03%
3 months+0.06%
6 months+26.26%
Current year+34.92%
Current year 22.13
Extreme 22.13
32.56
1 year 19.9
Extreme 19.9
32.56
3 years 11.89
Extreme 11.89
32.56
5 years 5.24
Extreme 5.24
32.56
10 years 0.94
Extreme 0.9414
32.56
Manager TitleAgeSince
Chief Executive Officer 65 01/01/2024
Director of Finance/CFO 55 01/01/2024
Chief Tech/Sci/R&D Officer 62 01/06/2025
Director TitleAgeSince
Director/Board Member 48 15/07/2026
Director/Board Member - 15/07/2026
Director/Board Member - 15/07/2026
Date Insider Type Main position Quantity % Market Cap. Importance
15/07/26 Issuer sale

Director

-63,583 0.0519%
15/07/26 Issuer sale

Director

-1,30,857 0.1069%
15/07/26 Issuer sale

Executive/Senior Manager

-10,51,183 0.8587%
Change 5-day change 1-year change 3-year change Capi.($)
+0.03%-.--% - - 385.5Cr
+0.45%+1.76%+54.96%+118.11% 1,13500Cr
+0.94%+4.20%+39.86%+75.69% 64TCr
+0.39%+0.46%+25.77%+97.40% 50TCr
+1.43%+4.56%+46.20%+66.91% 38TCr
-3.21%-3.66%+60.72%+35.68% 36TCr
-0.41%+2.23%+22.48%+48.54% 29TCr
+0.23%+3.28%+2.57%+21.89% 27TCr
+1.22%+2.81%+52.40%+63.37% 24TCr
+1.70%+1.60%+31.21%+102.44% 19TCr
Average +0.22%+1.60%+37.35%+70.00% 44.49TCr
Weighted average by Cap. +0.24%+1.63%+41.40%+81.03%
Logo Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing medicines for patients living with rare and difficult-to-treat diseases. The Company markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.
Employees
182
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Catalyst Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. CPRX Stock